EyePoint Pharmaceuticals, Inc. (EYPT)
| Market Cap | 579.39M |
| Revenue (ttm) | 56.04M |
| Net Income (ttm) | -146.78M |
| Shares Out | 68.81M |
| EPS (ttm) | -2.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 601,853 |
| Open | 9.06 |
| Previous Close | 8.92 |
| Day's Range | 8.37 - 9.13 |
| 52-Week Range | 3.91 - 13.99 |
| Beta | 1.64 |
| Analysts | Strong Buy |
| Price Target | 24.75 (+193.94%) |
| Earnings Date | Aug 6, 2025 |
About EYPT
EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related ma... [Read more]
Financial Performance
In 2024, EyePoint Pharmaceuticals's revenue was $43.27 million, a decrease of -5.97% compared to the previous year's $46.02 million. Losses were -$130.87 million, 84.9% more than in 2023.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for EYPT stock is "Strong Buy." The 12-month stock price forecast is $24.75, which is an increase of 193.94% from the latest price.
News
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patie...
EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026
EyePoint Pharmaceuticals, Inc.'s Duravyu shows promising Phase 2 results in DME, supporting a slightly risky 'Buy' call ahead of pivotal Phase 3 readouts in 2026. Duravyu's potential for less frequent...
EyePoint Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of ...
EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration
– Over 400 patients enrolled and randomized over a seven-month period, driven by strong physician and patient interest –
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patien...
EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants George Elston - Executive Vice President & Chief Financial Officer Jay Duker ...
EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments
– Enrollment continues to exceed expectations in DURAVYU ™ Phase 3 wet AMD clinical trials with over 90% of patients randomized into the LUGANO trial and over 50% into the LUCIA trial, reinforcing con...
EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025
WATERTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives o...
EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference
WATERTOWN, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives o...
EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2024 Earnings Call Transcript
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2024 Earnings Conference Call March 5, 2025 8:30 AM ET Company Participants George Elston - EVP and CFO Jay Duker - President and CEO Ramiro Ribeiro - ...
EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments
– Enrollment exceeding expectations in DURAVYU ™ Phase 3 wet AMD clinical trials with LUGANO over 50% enrolled and LUCIA recruiting ahead of schedule – – Positive Phase 2 VERONA clinical trial of DURA...
EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025
WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...
EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference
– Company presentation scheduled on Tuesday, March 4 th at 9:10am ET – – EyePoint to provide enrollment update for ongoing DURAVYU™ Phase 3 pivotal program in wet AMD and additional subgroup analyses ...
EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival
EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections required compared to Eylea and Vabysmo. Positive Phase 2 DME data and ongoin...
EyePoint to Present at Guggenheim SMID Cap Biotech Conference
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...
EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D.
WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...
EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration
– Topline data for Phase 3 pivotal program anticipated in 2026 – WATERTOWN, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing an...
EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity
EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME, with one phase 3 trial ongoing and one more planned for 2025. EYP-1901 demonstrated strong safety...
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering
WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...
EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema
- DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a gain of +8.9 letters compared to baseline -
EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration
– Second Phase 3 LUCIA pivotal trial first patient dosing expected by end of 2024 – – Topline data anticipated in 2026 – WATERTOWN, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, I...
EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
- Appointment strengthens leadership team as Company approaches dosing of patients in Phase 3 pivotal trials of DURAVYU™ in wet AMD in 2024 - - Appointment strengthens leadership team as Company appro...